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Objectives. We sought to define effects of glibenclamide, a
sulfonylurea known to block ATP-dependent potassium (KATP)
channels, and Nv-nitro-L-arginine methyl ester (L-NAME), an
L-arginine analog known to block nitric oxide (NO) synthesis, on
coronary vascular responsiveness to adenosine.
Background. The role of adenosine in coronary flow regulation
becomes increasingly important when KATP channel function or
NO synthesis is impaired. Both variables are potentially altered in
patients with coronary artery disease taking a sulfonylurea.
Methods. Dose-response curves relating coronary conductance
to plasma adenosine concentration were obtained by using intra-
coronary infusions of adenosine (10 to 1,000 mg/min) in chroni-
cally instrumented dogs.
Results. ED50, the plasma concentration of adenosine needed to
produce 50% of the maximal increase in conductance under
baseline conditions, increased threefold after either 1 or 10 mg/kg
of L-NAME. ED50 also increased in response to glibenclamide in a
dose-related fashion (5.7-fold increase per 1 mg/kg body weight of
glibenclamide). Effects of combined blockade of KATP channels
and NO synthesis were additive, with increases in ED50 as high as
15-fold. Both L-NAME and glibenclamide increased systemic
pressure and reduced coronary conductance, confirming the roles
of NO and KATP channels in regulating coronary and systemic
vascular tone under rest conditions as well as during stress.
Conclusions. Coronary vascular responsiveness to adenosine is
blunted in vivo by both L-NAME and glibenclamide. Effects of the
sulfonylurea and blockade of NO synthesis are additive and can
limit coronary vasodilation as well as other responses involving
KATP channels and NO.
(J Am Coll Cardiol 1998;31:816–22)
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It is now established that nitric oxide (NO) and ATP-
dependent potassium (KATP) channels play important roles in
coronary flow regulation. NO exerts a tonic vasodilating effect
on conduit and resistance vessels in humans (1,2) and experi-
mental animals (3–5). Blockade of NO synthesis with
L-arginine analogs blunts reactive hyperemia (6,7) and can
limit flow increases during exercise in the presence of a
coronary stenosis (7). Likewise, blockade of KATP channels
with glibenclamide (glyburide) can reduce rest coronary flow
(8–10), diminish flow increases during reactive hyperemia
(11,12) and limit flow responses to exercise (10). At the highest
rates of administration studied in intact animals, glibenclamide
can reduce rest flow sufficiently to induce myocardial ischemia
(13).
Adenosine, the prototypic agent used to produce maximal
coronary vasodilation, assumes increasing importance when
KATP channel function or NO synthesis is impaired. When
KATP channels are blocked with a sulfonylurea such as gliben-
clamide, endogenously produced adenosine plays a pivotal role
in maintaining rest flow in the presence of coronary stenoses
and in effecting coronary vasodilation during a stress such as
exercise (14). Because vasodilator responses to adenosine are
partly mediated by endothelial release of NO (15), it is also
possible that coronary vascular responses to adenosine are
blunted in the presence of endothelial dysfunction. However,
existing studies of effects of blockade of NO synthesis on
responses to adenosine (16–18) have given variable results.
Clinical interest in administration of sulfonylureas relates
primarily to the use of these agents in the treatment of
non-insulin–dependent diabetes mellitus. Engler and Yellon
(19) have suggested that KATP channel blockade, by adversely
affecting myocardial preconditioning responses to ischemia,
could have contributed to the increased cardiovascular mor-
tality reported in patients treated with tolbutamide in the
University Group Diabetes Program study. Although effects of
sulfonylureas on coronary vasodilator responses are also of
interest, experimental studies of the coronary circulation have
employed doses of these agents that are at least an order of
magnitude larger than those used clinically. In addition, coro-
nary vasoregulation is likely to be affected by the endothelial
dysfunction occurring in both diabetes and coronary artery
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disease. Endothelial dysfunction could potentially accentuate
coronary vascular effects of KATP channel blockade by blunting
alternative vasodilating mechanisms, that is, endothelial pro-
duction of NO.
The present study was undertaken to determine whether,
and to what degree, coronary vascular responsiveness to
adenosine is altered by blockade of NO synthesis and KATP
channels, both singly and in combination. Effects of gliben-
clamide and Nv-nitro-L-arginine methyl ester (L-NAME), an
L-arginine analog known to block NO synthesis, were exam-
ined in vivo in chronically instrumented dogs, thereby avoiding
effects of anesthesia or thoracotomy, or both. To simulate the
clinical situation, glibenclamide was administered systemically
rather than by intracoronary infusion, and in smaller doses
than previously employed experimentally. The lower dose
levels also avoided possible effects of glibenclamide unrelated
to KATP channels (20).
Methods
Studies were performed in male or female mongrel dogs by
using procedures and protocols concordant with the Position
of the American Heart Association on Research Animal Use.
Experimental preparation. Nineteen male or female dogs
weighing 23 to 44 kg were fitted with instruments after an
overnight fast and the usual period of on-site conditioning.
After premedication with Innovar-Vet (fentanyl, 0.4 mg/ml,
and droperidol, 20 mg/ml, 1 ml intramuscularly), anesthesia
was induced with sodium thiamylal (20 mg/kg body weight
intravenously) or methohexital (11 mg/kg). After intubation
and institution of mechanical ventilation, a surgical plane of
anesthesia was maintained with a gas mixture of nitrous oxide
(;60%), oxygen (;40%) and halothane (1% to 2%). A left
thoracotomy was performed under sterile conditions and plastic
catheters were placed into the descending aorta and left atrium. A
Konigsberg micromanometer was inserted into the left ventricle
through the left ventricular apex. The proximal portion of the left
circumflex coronary artery (LCx, n 5 15) or left anterior descend-
ing coronary artery (LAD, n 5 4) was fitted with a Transonic
Systems transit time ultrasound flow probe (model 3RB on the
LCx, model 2SB on the LAD) and a hydraulic occluder. A
22-gauge angiocatheter connected to small-bore tubing was in-
serted into the artery distal to the flow probe. Bipolar pacing leads
were sewn onto the left atrial appendage. Potential collateral flow
through epicardial vessels was limited by ligating visible anasto-
moses between branches of the LCx and LAD. Catheters and
wires were exteriorized through the chest wall and placed in an
external jacket. The chest was closed and the pneumothorax
evacuated. Keflin (30 to 35 mg/kg intravenously or intramuscu-
larly twice daily) was administered for 1 to 3 days postoperatively,
and narcotic analgesia (Buprenex, 0.01 to 0.02 mg/kg subcutane-
ously every 8 to 12 h) was given as needed for postoperative
discomfort. Catheters were flushed with saline solution and filled
with heparin every 1 to 2 days (10,000 U/ml for the LCx catheter
and 1,000 U/ml for other catheters). Aspirin (325 mg orally) was
given daily beginning on postoperative day 3. The dogs were
allowed to recover for $7 days before studies were initiated.
Study procedure. The dogs were studied while lightly se-
dated with Innovar-Vet and resting in a sling to which they had
previously been acclimated. Catheters used for pressure mea-
surement were connected to strain gauge transducers (Viggo-
Spectramed P23XL), with the zero reference level taken at
midchest. The strain gauges and the left ventricular microma-
nometer were connected to transducer preamplifiers (model
1147, Gould, Inc.). Ultrasound flow probes were connected to
a Transonic Systems model T-206 meter; the zero flow levels
were established by momentary coronary artery occlusion.
Dose-response relations for adenosine were obtained by
infusing adenosine dissolved in isotonic saline solution into the
LCx (or LAD) and measuring steady state LCx (or LAD) flows
at infusion rates of 10, 30, 60, 100, 300, 600 and 1,000 mg/min;
infusion volumes were between 0.1 and 1.0 ml/min. Gliben-
clamide (Sigma Chemical) was prepared by dissolving
1.0 mg/kg in ;0.2 ml of dimethyl sulfoxide and 50 ml of normal
saline solution containing 3 mEq of sodium bicarbonate.
L-NAME was dissolved in isotonic saline solution.
Studies were performed on two separate days in 10 dogs.
On one day adenosine dose-response relations were obtained
under baseline conditions and after 0.3 and an additional
0.7 mg/kg of glibenclamide given intravenously. On the other
day, dose-response relations were obtained under baseline
conditions, after 1 mg/kg of L-NAME given into the left atrium,
and after 0.3 and an additional 0.7 mg/kg of glibenclamide.
Atrial pacing at 120 beats/min was used on both days. Blood
glucose levels were monitored periodically; in four dogs, an
intravenous infusion of 5% dextrose in water was initiated to
ensure that glucose levels remained above 3.3 mmol/liter. In
two dogs studied with graded intracoronary infusions of ace-
tylcholine (1 to 20 mg/min), L-NAME reduced peak coronary
flow responses by 66% and 68%, respectively. In the final three
dogs studied, plasma samples were obtained after each gliben-
clamide dose (on the day L-NAME was not given) for high
performance liquid chromatography measurements of gliben-
clamide levels (National Medical Services, Inc.).
To evaluate responses to a larger dose of L-NAME, aden-
osine dose-response relations were obtained in nine additional
dogs (all with LCx catheters) under baseline conditions and
Abbreviations and Acronyms
ANCOVA 5 one-way analysis of covariance
CI 5 confidence interval
ED50 5 the plasma concentration of adenosine needed to
produce 50% of the maximal increase in
conductance under baseline conditions
KATP 5 ATP-dependent potassium
LAD 5 left anterior descending coronary artery
LCx 5 left circumflex coronary artery
L-NAME 5 Nv-nitro-L-arginine methyl ester
L-NMMA 5 Nv-nitro-methyl-L-arginine
NO 5 nitric oxide
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after left atrial infusion of L-NAME, 10 mg/kg. In three dogs
studied with graded intracoronary infusions of acetylcholine (1
to 20 mg/min), L-NAME reduced peak coronary flow responses
by 86% to 97%.
The dogs were euthanized with an overdose of sodium
pentobarbital on completion of studies.
Data analysis. Hemodynamic data were monitored contin-
uously in analog form (Video 516YT) and digitized intermit-
tently at a sampling rate of 180 Hz for 30 s. Average values for
individual variables were calculated during each 30-s period in
which data were digitized (DataFlow, Crystal Biotech). An
index of coronary conductance was calculated as the quotient
of steady state coronary flow and the corresponding mean
aortic pressure. Plasma adenosine levels were calculated with
the approach of Olsson (21) by dividing each drug infusion rate
by the steady state coronary flow and (1 2 hematocrit).
Adenosine dose-response data were fitted to a sigmoid model
of the form: f(x) 5 {exp(Ax2)/[B1C exp(Ax2)] 1 D}, where
x 5 log plasma adenosine concentration, f(x) 5 conductance
and A, B, C and D are constants. The adenosine concentration
needed to increase conductance to 50% of the increment
between initial and maximal values on the baseline study was
designated ED50 and expressed in mmol/liter.
Data are presented as mean value 6 SEM. In dogs given
both L-NAME and glibenclamide, baseline hemodynamic vari-
ables and logarithmic values for ED50 on the two study days
were compared by paired t tests and their reproducibility was
assessed by the intraclass correlation coefficient. Measure-
ments did not differ significantly on the two days and the
intraclass correlation coefficients (0.60 to 0.78) indicated good
to excellent reproducibility (22). Baseline values on the two
days were therefore averaged. Data were then evaluated using
one-way analysis of covariance (ANCOVA) for repeated mea-
sures, with glibenclamide dose treated as a continuous vari-
able. The interaction term of the ANCOVA model for log
(ED50) was insignificant (p 5 0.67). Responses of log (ED50)
to L-NAME and glibenclamide were therefore evaluated from
the model variables, by using the adjusted means for L-NAME
and the linear regression coefficient for glibenclamide. In the
cases of aortic pressure, coronary conductance and coronary
blood flow, the interaction term of the ANCOVA model was
associated with a p value #0.10 and plots of the data supported
an interaction between L-NAME and glibenclamide. Effects of
L-NAME and glibenclamide in these cases were therefore
estimated separately. Responses to L-NAME were evaluated
by comparing values before and after administration of
L-NAME with the use of paired t tests. Responses to gliben-
clamide were evaluated separately on the two study days, by
using linear regression; on days when L-NAME was not given,
only the baseline values for that day were used in calculating
the responses to glibenclamide.
In dogs given only L-NAME, hemodynamic data and loga-
rithmic values for ED50 before and after L-NAME were
compared by paired t tests. All statistical tests were two-tailed,
with p , 0.05 considered statistically significant. The software
package used for data analysis was SYSTAT, version 5.03.
Results
Responses to glibenclamide and L-NAME. Baseline values
of arterial pH, pCO2, pO2 and hemoglobin averaged 7.36 6
0.01, 37 6 1.5 mm Hg, 88 6 2.3 mm Hg and 11.4 6 0.7 g/dl,
respectively. Values for log (ED50), hemodynamic variables
and blood glucose are shown in Table 1. Plasma glibenclamide
concentrations averaged 1.54 mmol/liter (range 1.40 to 1.70)
after 0.3 mg/kg and 6.14 mmol/liter (range 4.86 to 6.88) after
the total dose of 1.0 mg/kg.
Adenosine dose-response curves from individual dogs are
shown in Figures 1 (day of study with glibenclamide alone) and
2 (day of study with L-NAME and glibenclamide). Logarithmic
values of ED50 are shown as a function of glibenclamide dose
in Figure 3. Results of ANCOVA indicated that L-NAME
(1.0 mg/kg) significantly increased log (ED50) from 0.79 6 0.09
to 1.26 6 0.09 (adjusted mean 6 SEM, p 5 0.005). This
represents a threefold increase in the ED50 plasma concentra-
tion of adenosine, from 6.17 mmol/liter (95% confidence
interval (CI) 3.88 to 9.77) to 18.2 mmol/liter (95% CI 11.4 to
29.0). The log (ED50) response to glibenclamide was similar on




















Baseline 0.54 6 0.15 95 6 3.7 44 6 6.4 0.47 6 0.06 2,015 6 143 7.9 6 1.1
GB, 0.3 mg/kg 0.72 6 0.15 100 6 3.6 41 6 5.6 0.42 6 0.06 1,953 6 106 6.5 6 0.7
GB, 1.0 mg/kg 1.22 6 0.09 102 6 4.0 37 6 5.2 0.36 6 0.05 1,983 6 71 5.1 6 0.4
Study day 2
Baseline 0.49 6 0.18 91 6 3.3 48 6 7.0 0.53 6 0.07 1,792 6 191 5.8 6 0.3
L-NAME 0.86 6 0.21 109 6 4.7 48 6 7.4 0.45 6 0.07 1,900 6 158
GB, 0.3 mg/kg 1.16 6 0.20 113 6 4.3 48 6 7.4 0.43 6 0.07 1,815 6 117 5.6 6 0.7
GB, 1.0 mg/kg 1.68 6 0.23 109 6 4.1 47 6 6.9 0.44 6 0.06 1,786 6 113 5.1 6 0.4
*n 5 8. †n 5 9. Values are mean 6 SEM. dP/dt 5 first derivative of left ventricular pressure; ED50 5 the plasma concentration of adenosine needed to produce
50% of the maximal increase in conductance under baseline conditions; GB 5 glibenclamide; L-NAME 5 Nv-nitro-L arginine methyl ester.
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both study days, that is, with and without L-NAME (Figure 3).
The regression coefficient for glibenclamide dose was 0.76 6
0.11 (p , 0.0001), indicating a 5.7-fold increase in ED50 per
1 mg/kg of glibenclamide (95% CI 3.3 to 10.0). Thus, ED50 was
increased .15-fold by the combination of L-NAME and glib-
enclamide.
Aortic pressure increased in response to L-NAME (18 6
3.1 mm Hg, p 5 0.0003), and to glibenclamide when the
sulfonylurea was given in the absence of L-NAME (6.8 6
2.8 mm Hg per 1.0 mg/kg of glibenclamide, p , 0.0001).
However, when glibenclamide was given after L-NAME, aortic
pressure did not change further. Coronary conductance
showed a similar but directionally opposite pattern, decreasing
in response to L-NAME (0.53 6 0.07 to 0.45 6 0.07 ml/min per
mm Hg, p , 0.03) and to glibenclamide in the absence of
L-NAME (20.097 6 0.017 ml/min per mm Hg per 1.0 mg/kg of
glibenclamide, p , 0.0001), but not changing further when
glibenclamide was given after L-NAME. Coronary flow de-
creased in response to glibenclamide alone (26.92 6
1.47 ml/min per 1.0 mg/kg of glibenclamide, p , 0.0001), but it
was unchanged by L-NAME or glibenclamide after L-NAME.
Peak first derivative of left ventricular pressure (dP/dt) was
unaffected by either agent.
Response to larger dose of L-NAME. Baseline values of
arterial pH, pCO2, pO2 and hemoglobin in dogs given 10 mg/kg
of L-NAME averaged 7.39 6 0.01, 33 6 1.9 mm Hg, 84 6
2.3 mm Hg and 10.2 6 0.5 g/dL, respectively. After L-NAME,
the dose-response relation relating LCx conductance to plasma
adenosine concentration shifted to the right in each case, with
log (ED50) increasing from 0.56 6 0.16 to 1.06 6 0.22 (p 5 0.005)
(Fig. 4). This represents a 3.2-fold increase in ED50, from
3.64 mmol/liter (95% CI 1.59 to 8.34) to 11.5 mmol/liter (95%
CI 3.62 to 36.6), and is similar to that observed after 1 mg/kg
of L-NAME. Peak values of coronary conductance did not
change systematically (1.15 6 0.06 vs. 1.13 6 0.21 ml/min per
mm Hg, p 5 0.79). L-NAME increased mean aortic pressure by
20 6 5 mm Hg (105 6 4.2 to 125 6 4.1 mm Hg, p , 0.01) and
decreased LCx conductance by 19 6 3.1% (0.37 6 0.04 to
0.30 6 0.04 ml/min per mm Hg, p , 0.05). These responses
were also similar to those after 1 mg/kg of L-NAME.
Discussion
The present study demonstrates that coronary vascular
responsiveness to adenosine is impaired by both L-NAME and
glibenclamide and that effects of the two agents are additive.
The physiologic relevance of the findings is supported by their
occurrence in an in vivo setting in which mechanisms that
could potentially counteract effects of sulfonylureas or block-
ade of NO synthesis, or both, remained available.
Figure 1. Dose-response relations relating coronary conductance and
plasma adenosine concentration under baseline conditions and after
glibenclamide (GB), 0.3 mg/kg, and an additional 0.7 mg/kg. L 5 liter.
Figure 2. Dose-response relations relating coronary conductance and
plasma adenosine concentration under baseline conditions (control),
after L-NAME, 1 mg/kg, and after glibenclamide (GB), 0.3 mg/kg, and
an additional 0.7 mg/kg. L 5 liter.
Figure 3. Logarithmic values of (ED50) as a function of glibenclamide
dose in the absence and presence of L-NAME (1 mg/kg). Log (ED50)
is increased by L-NAME at any glibenclamide level. The slope of the
regression line relating log (ED50) to glibenclamide dose is similar with
and without L-NAME. Vertical bars represent 6 1 SEM. L 5 liter.
Figure 4. Logarithmic values of (ED50) before (control) and after
L-NAME, 10 mg/kg. *p 5 0.005. L 5 liter.
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KATP channel–adenosine interactions and effects of gliben-
clamide. The reductions in coronary vascular responsiveness
to adenosine after glibenclamide in this study are similar in
direction but smaller in magnitude than those reported by
groups that administered larger doses of glibenclamide system-
ically. Belloni and Hintze (23) found that 2.0 mg/kg of gliben-
clamide produced a 10-fold increase in the ED50 for changes in
coronary conductance produced by intravenous adenosine in
chronically instrumented dogs with muscarinic and beta-
adrenergic receptors blocked pharmacologically. Clayton et al.
(12) reported that increments in coronary flow in response to
intracoronary adenosine in open chest dogs were blunted to a
still greater degree after 3 mg/kg of glibenclamide. Taken
together, these reports and the present study indicate that
glibenclamide blunts adenosine-induced coronary vasodilation
in a dose-dependent manner over a wide range of sulfonylurea
concentrations.
Although plasma or serum glibenclamide levels have not
been reported in previous in vivo studies of coronary vascular
responses, the larger systemic doses employed in previous
studies must have resulted in higher blood levels than in the
present study. Perfusate concentrations of glibenclamide in
most studies of isolated hearts, arteries or myocytes have also
exceeded the plasma or serum levels reported in man, often by
one to two orders of magnitude. Although comparisons with
levels achieved in patients involve a variety of factors that
cannot be assessed fully, our glibenclamide values after admin-
istration of 0.3 mg/kg may be of interest in relation to those
reported in diabetic patients, whose daily doses of gliben-
clamide can be as high as 20 mg. After a single oral dose of
2.5 mg of glibenclamide, Ikegami et al. (25) found serum levels
to average 0.28 mmol/liter (138 ng/ml), with individual patients
showing levels as high as 0.47 mmol/liter. After 5 mg, other
investigators (26 –31) observed average levels of 0.28 to
0.73 mmol/liter. Coppack et al. (32) reported values averaging
0.31, 0.50 and 0.88 mmol/liter, respectively, after single 5-, 10-
and 20-mg doses. Information about steady state levels in
patients is limited and includes rather wide variability. In
patients taking 2.5 to 25 mg of glibenclamide daily, Sartor et al.
(28) reported a poor correlation between prescribed dose and
serum levels measured just before the usual daily dose. Indi-
vidual levels varied from 0 to 1.52 mmol/liter and averaged
0.48 mmol/liter. Huupponen et al. (33) also found a wide range
of values in patients taking 10 6 5 (mean 6 SD) mg daily.
Comparisons with studies employing continuous intracoro-
nary infusion of glibenclamide in intact animals are more
difficult because of uncertainty about first-pass extraction of
the sulfonylurea and increasing plasma levels with time. Rest
coronary flow in intact animals is decreased regularly by an
intracoronary dose of 50 mg/kg per min (9,10,14). This dose
also alters responses to exercise in the absence as well as the
presence of coronary stenosis (10). Intracoronary infusions of
glibenclamide sufficient to produce coronary artery concentra-
tions of 55 to 80 mmol/liter (27,000 to 39,000 ng/ml) compro-
mise rest flow to the point of ischemia (13).
The mechanism of interaction between adenosine and
KATP channels remains incompletely understood, particularly
under conditions in which intracellular ATP levels are normal
(23,24). Data from Song et al. (20) confirm that KATP channel
behavior is affected by levels of glibenclamide similar to those
in the present study, that is, 1 mmol/liter of glibenclamide
abolished the outward K1 current activated by pinacidil, a
KATP channel opener, in guinea pig atrial myocytes. The study
of Song et al. also indicates that the higher concentrations of
glibenclamide employed in several previous studies can have
effects that are not specific to KATP channels; that is, 30 mmol/liter
of glibenclamide blocked K1 current activated by a muscarinic
agonist and a guanosine triphosphate analog as well as aden-
osine.
Effects of L-arginine analogs. Although coronary vascular
effects of NO were first appreciated in conduit arteries, NO is
now known to dilate coronary resistance as well as epicardial
vessels in both experimental animals (3–7) and humans (1,2).
Jones et al. (34) reported that L-NAME constricts small
arteries and arterioles .100 mm, and Kuo et al. (35) demon-
strated that L-NMMA, another L-arginine analog, abolishes
flow-related vasodilation in porcine arterioles. In addition, as
discussed by Smith and Canty (6) and Duncker and Bache (7),
several studies have shown that L-arginine analogs blunt one or
more aspects of the reactive hyperemia response after tran-
sient coronary occlusion.
The present data demonstrate that L-NAME reduces cor-
onary vascular responsiveness to adenosine by itself, and
accentuates glibenclamide-induced reductions in adenosine
responsiveness. These findings may relate to observations,
recently summarized by Smits et al. (15), indicating that
vasodilator responses to adenosine are mediated in part by
endothelial release of NO. The present findings are also
compatible with the finding of Rubanyi and Vanhoutte (36)
that adenosine-induced relaxation in canine coronary artery
rings is reduced when endothelium is removed, and with
studies (37,38) indicating the presence of A2 purinoceptors on
endothelium as well as vascular smooth muscle. Sensitivity to
adenosine could be affected by any change in adenosine uptake
by endothelial cells or erythrocytes induced by L-NAME (or
glibenclamide). A further possibility suggested by Kontos and
Wei (39) is that arginine analogs directly influence the function
of KATP channels. In any event, the present data indicate that
adenosine-related effects of L-NAME are maximal at a dose of
1 mg/kg, which is an order of magnitude less than that used in
many earlier studies.
Our L-NAME data also clarify previously reported re-
sponses to adenosine. Parent et al. (16) found that Nv-nitro-
L-arginine attenuated flow responses to bolus intracoronary
administration of 100 ng/kg of adenosine in chronically instru-
mented dogs, whereas Canty and Schwartz (17) did not
observe a reduction in steady state mean flow during an
intracoronary infusion of 500 mg/min of adenosine after
L-NAME. Similarly, Gurevicius et al. (18) found that L-NAME
and L-NMMA did not reduce the canine flow response to
intracoronary adenosine, 800 mg/min, in open chest dogs. The
adenosine dose in the study of Parent et al. is comparable to
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the lower doses used in the present study, which also were
responsive to blockade of NO synthesis. The adenosine doses
in the studies of Canty and Schwartz and Gurevicius et al. are
at the higher end of the present adenosine dose range.
Effects of reduced endothelial production of NO on vaso-
dilator responses to adenosine bear on the clinical use of
acetylcholine/adenosine flow ratios to identify abnormalities in
coronary endothelial function (40). These measurements pre-
sume that maximal coronary vasodilation to adenosine is not
affected by endothelial dysfunction and can be used as a
reference to identify a reduced response to receptor-mediated
stimulation of NO production. The present data emphasize the
importance of using sufficiently large doses of intracoronary
adenosine to ensure that maximal vasodilation is reached.
Adenosine is typically infused at rates calculated to achieve
final blood concentrations of 1026, 1025 and 1024 mol/liter
(0.267, 2.67 and 26.7 mg/ml) (40). Because these calculations
are based on estimated rest values of coronary flow, and flow
normally can increase 4- to 5-fold in response to adenosine,
actual concentrations are proportionately lower. The use of
sufficient infusion rates to demonstrate that a maximal vasodi-
lating effect has been achieved seems advisable, particularly
when endothelial-mediated vasodilator mechanisms may be
compromised.
Clinical implications. The systematic reductions in coro-
nary conductance observed in response to L-NAME and
glibenclamide confirm that NO and KATP channels each play a
significant role in maintaining coronary vasodilator tone, even
under rest conditions. Endogenous adenosine production be-
comes particularly important in maintaining rest coronary flow
in the presence of coronary stenosis and in effecting coronary
vasodilation during periods of increased myocardial oxygen
demand (14). The additive impairment in adenosine-related
vasodilation caused by blockade of NO synthesis and sulfonyl-
urea administration is therefore most likely to be relevant to
patients with coronary artery disease and impaired endothelial
function given a sulfonylurea. A glibenclamide-related accen-
tuation of impaired coronary vasodilation would be expected
to be dose dependent and of greatest concern during situations
potentially leading to demand-induced ischemia. To our
knowledge, however, direct assessments of coronary vascular
responses to sulfonylureas in patients with coronary artery
disease are not yet available.
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